Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.
Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, Milroy R, Maughan TS, Falk SJ, Bond MG, Burt PA, Connolly CK, McIllmurray MB, Carmichael J. Anderson H, et al. Among authors: burt pa. Br J Cancer. 2000 Aug;83(4):447-53. doi: 10.1054/bjoc.2000.1307. Br J Cancer. 2000. PMID: 10945489 Free PMC article. Clinical Trial.
Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma.
White SC, Lorigan P, Middleton MR, Anderson H, Valle J, Summers Y, Burt PA, Arance A, Stout R, Thatcher N. White SC, et al. Among authors: burt pa. Cancer. 2001 Aug 1;92(3):601-8. doi: 10.1002/1097-0142(20010801)92:3<601::aid-cncr1360>3.0.co;2-k. Cancer. 2001. PMID: 11505405 Clinical Trial.
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
Danson S, Middleton MR, O'Byrne KJ, Clemons M, Ranson M, Hassan J, Anderson H, Burt PA, Fairve-Finn C, Stout R, Dowd I, Ashcroft L, Beresford C, Thatcher N. Danson S, et al. Among authors: burt pa. Cancer. 2003 Aug 1;98(3):542-53. doi: 10.1002/cncr.11535. Cancer. 2003. PMID: 12879472 Free article. Clinical Trial.
Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
Califano R, Griffiths R, Lorigan P, Ashcroft L, Taylor P, Burt P, Lee L, Chittalia A, Harris M, Faivre-Finn C, Thatcher N, Blackhall F. Califano R, et al. Lung Cancer. 2011 Sep;73(3):338-44. doi: 10.1016/j.lungcan.2011.01.001. Epub 2011 Feb 5. Lung Cancer. 2011. PMID: 21296449 Clinical Trial.
Dose intensity in small cell lung cancer.
Thatcher N, Lee SM, Woll PJ, Middleton M, Anderson H, Burt P, Stout R. Thatcher N, et al. Semin Oncol. 1998 Apr;25(2 Suppl 4):12-8; discussion 45-8. Semin Oncol. 1998. PMID: 9578057 Review.
Clinical and quality of life outcomes in the first United Kingdom randomized trial of endobronchial brachytherapy (intraluminal radiotherapy) vs. external beam radiotherapy in the palliative treatment of inoperable non-small cell lung cancer.
Stout R, Barber P, Burt P, Hopwood P, Swindell R, Hodgetts J, Lomax L. Stout R, et al. Radiother Oncol. 2000 Sep;56(3):323-7. doi: 10.1016/s0167-8140(00)00252-8. Radiother Oncol. 2000. PMID: 10974381 Clinical Trial.
33 results